Pharnext announces its 2020 Annual General Meeting to be held on July 17, 2020

Pharnext 
Pharnext announces its 2020 Annual General Meeting to be held on July 17, 
2020 
 
11-Jun-2020 / 08:28 CET/CEST 
Dissemination of a French Regulatory News, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
 
  · *Transformation of Pharnext's Board of Directors is proposed with a 
  slate of six new candidates * 
 
  · *Composition of the newly proposed Board is consistent with the 
  Company's plans to develop, file for approval and commercialize PXT3003 in 
  the US and Europe forCharcot-Marie-Tooth Type 1A disease* 
 
*PARIS, France, **8**:**0**0 a.m., June 1**1**, 2020 (CET) - *Pharnext [1] 
SA (FR0011191287 - ALPHA), a biopharmaceutical company pioneering new 
approaches to develop innovative drug combinations based on big genomics 
data and artificial intelligence, today announces that it will hold its 
Annual General Meeting ("AGM") on Friday, July 17, 2020, in a closed 
session, pursuant to specific French government rules surrounding the 
Covid-19 pandemic. 
As part of the AGM, Pharnext's Board of Directors is proposing to the AGM 
its transformation with a slate of six new Director candidates for 
three-year terms. The newly proposed Directors have a strong 
biopharmaceutical and business expertise focused on clinical development, 
neurology, strategy, transactions, value creation and governance experience. 
The new candidates are: 
 
  · Alexandre Berda - Managing Director of CB Lux, Pharnext's largest 
  shareholder. 
 
  · Jean Combalbert, Pharm.D., PhD - Founder and CEO of Epics Therapeutics 
  SA, Chairman of the Board for both Syndesi Therapeutics SA and Bioxodes 
  SA. Jean was earlier the CEO of Ogeda SA and has previously served in 
  senior development roles at Sanofi. , Jean has significant experience in 
  pre-clinical and clinical development. 
 
  · Joshua Schafer -Chief Strategy and Business Development Officer of 
  Mallinckrodt Pharmaceuticals and serves as a Board member of Shuttle 
  Pharmaceuticals. Josh was earlier head of the oncology franchise at 
  Astellas and held senior roles at Takeda. Josh has successfully led over 
  $16 billion in M&A transactions. 
 
  · David H. Solomon, PhD - Chief Executive Officer of Pharnext SA, David is 
  the non-executive Board Chairman at Advicenne SA. David was earlier the 
  CEO of Zealand Pharma (NASDAQ), and Silence Therapeutics (LSE). 
 
  · Prof. Lawrence Steinman, MD -Professor of Neurology and Neurological 
  Sciences, Pediatrics and Genetics at Stanford University. Larry is the GA 
  Zimmermann Chair of Neurological Sciences, Neurology and Pediatrics. 
 
  · Elisabeth Svanberg, MD, PhD -Chief Development Officer at Ixaltis SA, 
  Elisabeth serves as a Board member of Galapagos NV and Swedish Orphan 
  Biovitrum (SOBI), among others. Elisabeth has served in senior development 
  roles at Serono, Bristol-Meyers Squibb and Johnson&Johnson. 
 
If the shareholders approve the above Director appointments, the Board of 
Directors will consist of a total of 10 members, as 5 members will be 
stepping down from the Board, effective as of the AGM's date. In this 
context, the Board of Directors would be composed of Alexandre Berda, Pierre 
Bastid, Jean Combalbert, Kenneth Lee (representing Tasly Hong-Kong 
Pharmaceutical Ltd), Philippe Pouletty (representing Truffle Capital SAS), 
Michel de Rosen, Joshua Schafer, David H. Solomon, Lawrence Steinman, and 
Elisabeth Svanberg. 
Michel de Rosen, Chairman of the Board of Directors, commented: "I am 
delighted to propose such talented and experienced new candidates to join 
our Board of Directors at the AGM. I am confident that this transformation 
would significantly strengthen the Board in several key areas that are 
critical to Pharnext's next stages of growth and value creation. These new 
candidates would bring strong expertise in clinical development, neurology, 
business and transactional strategy. We are extremely grateful to the 
departing Directors for their energy, hard work and commitment to Pharnext, 
and in particular we extend a special thank you and appreciation to our 
founder, Dr. Daniel Cohen, for his vision and dedication. We are grateful 
that Daniel will serve as Chairman of our Scientific Advisory Board going 
forward." 
David H. Solomon, CEO, also commented: "I'm honored by the confidence the 
Board has placed in me in recommending my appointment as a Board Member. I 
am excited by the potential to have such a talented and experienced group of 
new Directors to join our Board. These new Directors would greatly assist 
and guide our management team during this important time in the Company's 
growth." 
About Pharnext 
Pharnext is an advanced clinical-stage biopharmaceutical company developing 
novel therapeutics for orphan and common neurodegenerative diseases that 
currently lack curative and/or disease-modifying treatments. Pharnext has 
two lead products in clinical development. PXT3003 completed an 
international Phase 3 trial with positive topline results for the treatment 
of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status 
in Europe and the United States. PXT864 has generated encouraging Phase 2 
results in Alzheimer's disease. Pharnext has developed a new drug discovery 
paradigm based on big genomics data and artificial intelligence: 
PLEOTHERAPY. Pharnext identifies and develops synergic combinations of 
drugs called PLEODRUG. The Company was founded by renowned scientists 
and entrepreneurs including Professor Daniel Cohen, a pioneer in modern 
genomics, and is supported by a world-class scientific team. More 
information at www.pharnext.com [2]. 
Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN 
code: FR0011191287). 
*Disclaimer * 
This press release contains certain forward-looking statements concerning 
Pharnext and its business. Such forward-looking statements are based on 
assumptions that Pharnext considers to be reasonable. However, there can be 
no assurance that the estimates contained in such forward-looking statements 
will be verified, which estimates are subject to numerous risks including 
the risks set forth in Pharnext's document de base filed with the AMF on 
June 2, 2016 under number I.016-0050 as well as in its annual periodic 
management reports and press releases (copies of which are available on 
www.pharnext.com) and to the development of economic conditions, financial 
markets and the markets in which Pharnext operates. The forward-looking 
statements contained in this press release are also subject to risks not yet 
known to Pharnext or not currently considered material by Pharnext. The 
occurrence of all or part of such risks could cause actual results, 
financial conditions, performance or achievements of Pharnext to be 
materially different from such forward-looking statements. Pharnext 
disclaims any intention or obligation to publicly update or revise any 
forward-looking statements, whether as a result of new information, future 
events, or otherwise. 
This press release and the information that it contains do not constitute an 
offer to sell or subscribe for, or a solicitation of an offer to purchase or 
subscribe for, Pharnext shares in any country. 
 
*Contacts* 
*Pharnext* 
Dr. David H Solomon 
Chief Executive 
Officer 
[e-mail] 
[3]m 
[phone] 
30 
*Media Relations         *Financial        *Investors**Relations 
(Europe)*                Communication     (U.S.)* 
Ulysse Communication     **(France)*       Stern Investor 
Bruno Arabian            Actifin           Relations, Inc. 
barabian                 Stéphane Ruiz     Jane Urheim 
[4]@ulysse-communicatio  [e-mail]  [e-mail] 
n.com                    [phone]    [phone] 
[phone]     11 15 
 
Regulatory filing PDF file 
 
File: Pharnext announces its 2020 Annual General Meeting to be held on July 
17, 2020 [5] 
1067845 11-Jun-2020 CET/CEST 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=cb3681285800d269b63272738266ab82&application_id=1067845&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=17d7eeaeab80c33fe70ecc5ba973abc0&application_id=1067845&site_id=vwd&application_name=news 
3: mailto:[e-mail] 
4: mailto:[e-mail] 
5: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=59fd60581d678a10ef3c1d85058ef439&application_id=1067845&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

June 11, 2020 02:29 ET (06:29 GMT)